Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEAR: PET/CT in Eosinophilic Asthma
NCT02937168Phase 4Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2017
- Primary completion
- May 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of reslizumab in asthma (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Global Lung Glycolysis at Week 4 and Lung Parenchyma Standardized Uptake Value Mean at Week 4. Started May 2017; status: terminated.
02
Drugs
reslizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02937168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937168.